{
    "clinical_study": {
        "@rank": "51869", 
        "arm_group": [
            {
                "arm_group_label": "Dose level 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose level 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose level 3", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed\n      Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy"
        }, 
        "brief_title": "A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The incidence of dose limiting toxicity (DLT) will be evaluated in cohorts of six patients\n      by starting OCV-C02 administration at dose level 1 (OCV-103 and OCV-104 at 0.3 mg each),\n      increasing the dose to dose level 2 (at 1 mg each), and then up to dose level 3 (at 3 mg\n      each). Once-weekly administration will be repeated four times in each treatment cycle, and\n      the incidence of DLT from Day 1 to Day 29 will be evaluated.\n\n      At the end of Cycle 1, patients who wish to continue OCV-C02 treatment and have provided\n      their written consent will be permitted to continue participation in the trial using the\n      same dosing schedule for each subsequent cycle as that for Cycle 1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have human leukocyte antigen (HLA)-A*24:02\n\n          -  Patients who have histologically-confirmed colorectal cancer (adenocarcinoma)\n\n          -  Patients with advanced or relapsed colorectal cancer who are refractory or intolerant\n             to standard chemotherapy\n\n          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of\n             0 to 1 at the time of enrollment in the trial.\n\n        Exclusion Criteria:\n\n          -  Patients who are HIV antibody test positive\n\n          -  Patients with an active infection\n\n          -  Patients who have or are suspected to have CNS metastasis of colon cancer (such as\n             metastatis of the brain)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801930", 
            "org_study_id": "293-12-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose level 1", 
                "description": "0.3 mg of each", 
                "intervention_name": "OCV-103 and OCV-104", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose level 2", 
                "description": "1 mg of each", 
                "intervention_name": "OCV-103 and OCV-104", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose level 3", 
                "description": "3 mg of each", 
                "intervention_name": "OCV-103 and OCV-104", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "OCV-C02", 
            "Colorectal Cancer", 
            "Antigen specific cancer immunotherapeutic"
        ], 
        "lastchanged_date": "June 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunto-gun", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy", 
        "overall_contact": {
            "last_name": "Drug Information Center", 
            "phone": "+81-3-6361-7314"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Kyoji Imaoka, Mr", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0", 
            "measure": "Dose Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "1 Month (29Day)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "September 2014"
            }, 
            {
                "description": "Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "September 2014"
            }, 
            {
                "description": "DTH reactions\uff0cCTL Measurement\uff0cBlood Regulatory T Cell Measurement", 
                "measure": "Immune-response", 
                "safety_issue": "No", 
                "time_frame": "29 days, September 2014"
            }
        ], 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}